SEELOS THERAPEUTICS
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.
SEELOS THERAPEUTICS
Industry:
Biotechnology Pharmaceutical
Founded:
1987-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.seelostherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
51.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics Font Awesome Wordpress Plugins
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Crinetics Pharmaceuticals
Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Keros Therapeutics
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Current Employees Featured
Founder
Stock Details
Investors List
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Grant - Seelos Therapeutics
The Lind Partners
The Lind Partners investment in Post-IPO Debt - Seelos Therapeutics
Official Site Inspections
http://www.seelostherapeutics.com Semrush global rank: 2.54 M Semrush visits lastest month: 6.93 K
- Host name: cloudproxy10160.sucuri.net
- IP address: 192.124.249.160
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Seelos Therapeutics"
Seelos Therapeutics (SEELQ) Company Profile & Description
Jun 12, 2025 Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous …See details»
Seelos Therapeutics - Crunchbase Company Profile & Funding
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics.See details»
Seelos Therapeutics - Overview, News & Similar companies
May 15, 2023 Seelos Therapeutics contact info: Phone number: (646) 293-2100 Website: www.seelostherapeutics.com What does Seelos Therapeutics do? Seelos Therapeutics, Inc. …See details»
Seelos Therapeutics, Inc. - Drug pipelines, Patents, Clinical
May 8, 2025 www.seelostherapeutics.com. Public Company | 1987 | New York, United States | 10-50 | OTC: SEELQ | www.seelostherapeutics.com. Last update 08 May 2025. Overview. …See details»
Seelos Therapeutics, Inc. - Dun & Bradstreet
Company Description: Seelos Therapeutics (formerly Apricus Biosciences) is focused on finding treatments for central nervous system disorders and rare diseases. It has a portfolio of about a …See details»
Seelos Therapeutics - Craft
Oct 29, 2024 Seelos Therapeutics has 3 employees across 2 locations and $2.2 m in annual revenue in FY 2023. See insights on Seelos Therapeutics including office locations, …See details»
Seelos Therapeutics Announces FDA Acceptance of Investigational …
Nov 8, 2021 NAF is a nonprofit organization established in 1957 to help persons with ataxia and their families. The Foundation's mission is to accelerate the development of treatments and a …See details»
Investors and Media - Seelos Therapeutics
Stock Information Investor and Media Relations Anthony Marciano Chief Communications Officer Seelos Therapeutics, Inc. [email protected] Offices Seelos Therapeutics, Inc. …See details»
Seelos Therapeutics Announces FDA Acceptance of ... - Nasdaq
Nov 8, 2021 NAF is a nonprofit organization established in 1957 to help persons with ataxia and their families. ... (Nasdaq: SEEL) 300 Park Avenue New York, NY 10022(646) 293 …See details»
New York biotech files for bankruptcy
Nov 22, 2024 After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for bankruptcy. The New York-based company’s chapter …See details»
The Science of Seelos - seelostherapeutics.com
Seelos intends to become a leading biopharmaceutical company focused on neurological and psychiatric disorders, including orphan indications by: Advancing SLS-002 for Acute Suicidal …See details»
Clinical Trials - Seelos Therapeutics
Advancing Multiple Programs Seelos Therapeutics is exploring new ways to think about and treat central nervous system (CNS) disorders in neurological diseases and disorders and in rare …See details»
Seelos Therapeutics Completes Acquisition of Trehalose from
Feb 19, 2019 Diversifies Seelos’ pipeline in rare diseases Collaborates with Team Sanfilippo Foundation in development of Trehalose in Sanfilippo syndrome NEW...See details»
Seelos Therapeutics Announces FDA Acceptance of Investigational …
NAF is a nonprofit organization established in 1957 to help persons with ataxia and their families. The Foundation's mission is to accelerate the development of treatments and a cure while …See details»
Seelos Announces Second Postponement of its Annual Meeting of …
Oct 24, 2024 Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous …See details»
Seelos Therapeutics-Seelos Therapeutics, Inc.-企业详情-InvestGO …
Dec 31, 2015 查看医药魔方InvestGO®数据库Seelos Therapeutics的公司信息。Seelos Therapeutics（Seelos Therapeutics, Inc.），公司简介：Seelos Therapeutics, Inc., a clinical …See details»
Careers - Seelos Therapeutics
Come Grow with Us – Add to the Value of Seelos Seelos Therapeutics places significant value on fostering and enhancing the talents and growth of our colleagues – both the person and the …See details»
Keros Therapeutics Announces Initial Topline Results from the …
Mar 31, 2025 In DMD patients, heart muscle cells progressively die and are replaced with scar tissue. This cardiomyopathy eventually leads to heart failure, which is currently the leading …See details»
Press Releases - Seelos Therapeutics
Press Releases - Seelos Therapeutics ... Press ReleasesSee details»
Privacy Policy - Seelos Therapeutics
Where we hold personal information about you with your consent or for the performance of a contract with you, you also have the right to ask us to provide you with the personal …See details»